The largest study on serum
adiponectin levels in breast cancer patients is reported from South Korea.
The authors also noted an increase in the values of anti-inflammatory
adiponectin, an adipokine again connected with glucose maintenance and insulin sensitivity.
Adiponectin, an adipokine belonging to the complement factor C1Q protein family [1], is expressed in liver sinusoid endothelial cells, skeletal muscle and bone-forming cells as well as in adipocytes [2-4].
Adiponectin is a protein hormone with anti-inflammatory and insulin-sensitizing properties that plays an important role in a number of metabolic processes such as glucose regulation and fatty acid oxidation.
Each of seven mice per group was selected using blood glucose levels and body weight, and the changes in the body weight, epididymal fat weights, serum
adiponectin and leptin levels, adipose
adiponectin contents and liver triglyceride contents were monitored.
According to an Endocrine Society-led study, race and pre-pregnancy body mass index (BMI) both affect leptin and
adiponectin levels.
Adiponectin is mostly produced in adipose tissue [16].
Adiponectin, an adipocyte-specific cytokine, exhibits anti-inflammatory property and protective effects against obesity-related diseases (6).
The second mechanism is that obesity alters levels of adipokines secreted from adipose tissue (resistin, leptin,
adiponectin, and proinflammatory cytokines such as interleukin-6 and tumor necrosis factor-[alpha]).